Day: March 29, 2022

NEW YORK, March 29, 2022 (GLOBE NEWSWIRE) — Better Choice Company Inc. (NYSE American: BTTR) (the “Company” or “Better Choice”), a pet health and wellness company, today reported its financial results for the fourth quarter and year ended December 31, 2021. “The fourth quarter of 2021 was a strong quarter for Better Choice. In spite of unprecedented supply chain disruptions felt across the consumer-packaged goods industry, we were able to deliver 18% quarterly net sales growth year-over-year, driven by 227% growth in International sales and 6% growth in E-commerce sales. This quarter, our supply chain and logistics team did a fantastic job navigating supply chain pressures to satisfy our growing customer demand and pivoted when needed with one goal in mind – to keep our product on the shelf for our loyal and growing consumer...

— Achieved $11.2 Million in Net Revenue in 2021 —— Expanded Coverage for EYSUVIS® to 118 Million Commercial Lives and 7.1 Million Medicare Lives —— KPI-012 Phase 1b Clinical Data Accepted for Presentation at ARVO; Initiation of Phase 2/3 Clinical Trial of KPI-012 expected in 4Q 2022 —— Conference Call and Webcast at 8:00 a.m. ET — ARLINGTON, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update. “In recent months, we have made meaningful progress toward our goal of establishing...

BEIJING, March 29, 2022 (GLOBE NEWSWIRE) — Genetron Holdings Limited (“Genetron Health” or the “Company”, NASDAQ: GTH), a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, today announced its unaudited preliminary financial results for the fourth quarter and full year ended December 31, 2021. 2021 and Recent Business HighlightsTherapy Selection:As of December 31, 2021, the Company had 58 hospital partners, of which 30 were IVD hospital partners. Genetron Health is continuing to enhance its in-hospital sales effort.Early Screening:The Company successfully introduced HCCscreen™ in China as an LDT service for hepatocellular carcinoma (HCC), along with establishing collaborations with channel partners...

SHANGHAI, China, March 29, 2022 (GLOBE NEWSWIRE) — Clover Biopharmaceuticals, Ltd. (Clover; HKEX: 02197), a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today reported financial results for the year ended December 31, 2021. “2021 was a remarkable year for Clover. We announced positive Phase 2/3 data for our COVID-19 vaccine candidate, raised significant capital including completing an IPO, and expanded our headcount to establish global development capabilities and prepare for commercial launch. We carried this momentum into the first quarter of 2022 by announcing exciting preliminary booster data against Omicron, results that drive us closer to achieving our vision of empowering humanity with a healthier future through transformative science,” said Joshua Liang, Chief...

F2021 Revenue More than Doubles to $8.15M; F2022 Revenue Guidance Exceeding $10M TORONTO, March 29, 2022 (GLOBE NEWSWIRE) — Clear Blue Technologies International Inc. (“Clear Blue” or “the Company”) (TSXV: CBLU), today announces its financial results for the year ended December 31, 2021, F2022 guidance and outlook, and the details for its quarterly conference call, which will take place on Tuesday, March 29, 2022, at 11 am Eastern (details below). All figures are in Canadian dollars unless stated otherwise. F2021 Financial Results2021 revenue was a record $8,148,659, a 103% increase over 2020; Gross profit was $2,255,460 (or 28%) a 78% increase from the previous comparative period ($1,266,999 or 31%); Non-IFRS Adjusted EBITDA for 2021 was $(2,563,334) as compared to $(3,590,285) for 2020; Telecom Vertical revenues grew by 182%...

Unveils Bioleum™ Breakthrough; A Carbon Neutral Crude Oil Capable of Replacing Fossil Crude VIRGINIA CITY, Nev., March 29, 2022 (GLOBE NEWSWIRE) — Comstock Mining Inc. (NYSE: LODE) (“Comstock” and the “Company”) today announced its 2021 results, summary of transactions completed in 2021, and our new business outlook. Selected Strategic HighlightsApproved a new strategy with a mission of enabling systemic decarbonization and a vision of a net zero carbon world. Acquired Comstock Innovations, formerly Plain Sight Innovations, with a portfolio of intellectual property that contributes to global decarbonization by efficiently converting massive supplies of unused and under-utilized woody-biomass resources into cellulosic ethanol, renewable diesel, sustainable aviation fuel, and other drop-in fuels. Acquired LINICO Corporation and...

Announces Expansion of Novel Immuno-Oncology Therapeutic Portfolio with Addition of Anti-Siglec-15 In-licensed from Biosion (PYX-106) Introduces First Internally Developed IO Candidate Anti-KLRG1 (PYX-102) Cash Runway Sufficient for Multiple Milestones Through Third Quarter 2024 Company to Host Conference Call and Webcast Today at 8:00 a.m. ET CAMBRIDGE, Mass., March 29, 2022 (GLOBE NEWSWIRE) — Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today provided a corporate and financial update and reported financial results for the full year ended December 31, 2021. “We have had a highly productive start to 2022, advancing our lead programs toward first-in-human clinical trials while executing our strategy of identifying the...

– Announced Global Collaboration Agreement with Sanofi for Oncology, Autoimmune and Inflammation Targets; IGM to Receive $150 Million Upfront Payment and potentially more than $6 Billion in Aggregate Development, Regulatory and Commercial Milestones – – Ongoing Progress in Clinical Programs with Two Phase 2 Studies of Two Doses of IGM-2323, 100 mg and 300 mg, in Patients with DLBCL and FL Initiated – – Company to Host Conference Call and Webcast Today at 8:00 a.m. EST – MOUNTAIN VIEW, Calif., March 29, 2022 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing IgM antibodies, today announced its financial results for the fourth quarter and full year ended December 31, 2021 and provided an update on recent developments. “IGM continues to make progress in...